Venetoclax and Decitabin Based Conditioning Regimen Followed With Post-HSCT Decitabin Maintenance Therapy in TP53 Mutant AML/MDS Patients

Inclusion Criteria: 1. AML or MDS diagnosed according to 2016 WHO criteria with TP53 mutation before enrollment; 2. Aged from 12 to 70 years; 3. The Eastern Cooperative Oncology Group (ECOG) performance score of 0-2; 4. Creatinine clearance rate ≥ 60 mL/min (according to Cockcroft-Gault formula); 5. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≥ 3× upper limit of normal range (ULN), total bilirubin ≤ 2×ULN; 6. Left ventricular ejection fraction (LVEF) assessed by echocardiography (ECHO) ≥ 45%; 7. Life expectancy \> 8 weeks; 8. Sign the informed consent voluntarily, understand and comply with all trial requirements. Exclusion Criteria: 1. Active autoimmune diseases, such as SLE, rheumatoid arthritis, etc. 2. Current active cardiovascular disease with clinically significance, such as uncontrolled arrhythmias, uncontrolled hypertension, congestive heart failure, any grade 3 or 4 heart disease determined by the New York Heart Association (NYHA) functional classification, or a history of myocardial infarction within the 6 months prior to screening; 3. Other serious medical conditions (e.g., advanced infection) that may limit the patient's participation in the trial; 4. Known human immunodeficiency virus (HIV) infection, or drug-uncontrolled chronic infection of hepatitis B virus (HBV-DNA \> 1000IU/ml) or hepatitis C virus (anti-HCV positive); 5. Pregnant or lactating women; 6. Fail to understand, comply with the study protocol or sign the informed consent form.